drugset / Trial / NCT03325387

A Study of Multiple Doses of LY3305677 in Healthy Participants

NCT03325387

Phase 1 Completed 56 enrolled Eli Lilly and Company
RandomizedParallel-groupDouble-blindBasic science

Summary

The purposes of this study are to determine: * The safety of LY3305677 and any side effects that might be associated with it. * How much LY3305677 gets into the bloodstream and how long it takes the body to remove it in healthy participants, including those of Japanese origin. * The effect LY3305677 has on the body, particularly the effect on blood glucose levels. This study will last approximately 17 weeks not including screening. Screening is required within 4 weeks prior to start of the study. This study is for research purposes only and is not intended to treat any medical conditions.

Timeline

Start
2017-10-27
Primary completion
2018-08-03
Completion
2018-08-03

Drugs

EvaluationDrugModalityDoseRoute
Subject Mazdutide Protein / enzyme biologic Subcutaneous

Indications

No indication recorded.